VERAXA

VERAXA Biotech is the fusion of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, both spin-offs from the European Molecular Biology Laboratory (EMBL), Europe's most renowned life sciences research and instrumentation development institution, which leads in microfluidics-based screening technologies and their global applications.The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation techniques enable the rapid generation of antibodies against the most complex target molecules, and can refine the target product profile of existing monoclonal antibody candidates in oncology or precision medicine. VERAXA is the preferred licensing and collaboration partner for the global biotechnology and pharmaceutical industries.